Agios Pharmaceuticals, Inc. (AGIO)

Price$28.29

Value ScoreC

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-11.04%

Price vs S&P 500 (4W)1.81%

VGM Score60.04

Market Capitalization$1.68B

P/E Ratio (Annual)2.61x

All Metrics

Book Value / Share (Quarterly)$18.69

P/TBV (Annual)1.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)55.97%

Cash Flow / Share (Quarterly)$-6.48

Price vs S&P 500 (YTD)-4.23%

Gross Margin (TTM)90.04%

Net Profit Margin (TTM)-639.84%

EPS (TTM)$-7.25

10-Day Avg Trading Volume0.90M

EPS Excl Extra (TTM)$-7.25

Revenue Growth (5Y)4.67%

EPS (Annual)$-7.12

ROI (Annual)-34.60%

Gross Margin (Annual)88.26%

Net Profit Margin (5Y Avg)-445.03%

Cash / Share (Quarterly)$12.42

Revenue Growth QoQ (YoY)137.75%

P/E Normalized (Annual)2.61x

ROA (Last FY)-31.82%

Revenue Growth TTM (YoY)78.34%

EBITD / Share (TTM)$-8.07

ROE (5Y Avg)13.77%

Operating Margin (TTM)-719.97%

Cash Flow / Share (Annual)$-6.46

P/B Ratio1.52x

P/B Ratio (Quarterly)1.81x

Net Income / Employee (Annual)$-765,800

EV / Revenue (TTM)23.75x

ROA (TTM)-31.66%

EV / EBITDA (TTM)2.48x

EPS Incl Extra (Annual)$-7.12

Current Ratio (Annual)11.46x

Quick Ratio (Quarterly)12.80x

3-Month Avg Trading Volume0.99M

52-Week Price Return-15.75%

Revenue / Employee (TTM)$122,500

Tangible BV / Share (Quarterly)$15.87

P/S Ratio (Annual)31.14x

Asset Turnover (Annual)0.04x

52-Week High$46.00

Operating Margin (5Y Avg)-532.96%

EPS Excl Extra (Annual)$-7.12

CapEx CAGR (5Y)-21.96%

Tangible BV CAGR (5Y)24.00%

26-Week Price Return-3.12%

Quick Ratio (Annual)10.52x

13-Week Price Return2.20%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.19x

Enterprise Value$1.57B

Revenue / Share Growth (5Y)0.19%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)28.77%

Revenue / Employee (Annual)$100,200

Inventory Turnover (Annual)0.21x

Pretax Margin (Annual)-765.89%

Cash / Share (Annual)$14.62

3-Month Return Std Dev69.88%

Gross Margin (5Y Avg)90.54%

Net Income / Employee (TTM)$-784,100

ROE (Last FY)-34.60%

EPS Basic Excl Extra (Annual)$-7.12

Receivables Turnover (TTM)6.78x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-7.25

Receivables Turnover (Annual)7.36x

ROI (TTM)-34.11%

P/S Ratio (TTM)25.47x

Pretax Margin (5Y Avg)-421.16%

Revenue / Share (Annual)$0.93

Tangible BV / Share (Annual)$20.00

Price vs S&P 500 (52W)-40.12%

Year-to-Date Return3.93%

5-Day Price Return1.04%

EPS Normalized (Annual)$-7.12

ROA (5Y Avg)12.81%

Net Profit Margin (Annual)-764.01%

Month-to-Date Return-3.78%

Cash Flow / Share (TTM)$-3.84

EBITD / Share (Annual)$-8.05

EPS Growth (3Y)-24.03%

Operating Margin (Annual)-873.87%

ROI (5Y Avg)13.76%

EPS Basic Excl Extra (TTM)$-7.25

P/TBV (Quarterly)1.41x

P/B Ratio (Annual)1.33x

Inventory Turnover (TTM)0.20x

Pretax Margin (TTM)-641.38%

Book Value / Share (Annual)$20.41

Price vs S&P 500 (13W)-6.05%

Beta0.62x

P/FCF (Annual)58.74x

Revenue / Share (TTM)$1.12

ROE (TTM)-34.11%

52-Week Low$22.24

vGradeC

gGradeB

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-1.69est. -1.84

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.06

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
AGIOAgios Pharmaceuticals, Inc.	C	B	C	$28.29
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Agios Pharmaceuticals develops small-molecule medicines for rare hematologic diseases through cellular metabolism pathways. Its lead product, Pyrukynd (mitapivat), is a pyruvate kinase activator for hemolytic anemias, with additional pipeline candidates targeting sickle cell disease and myelodysplastic syndrome-associated anemia. The company addresses significant unmet medical needs in rare blood disorders.